CRI will begin delivering RISE Manchester, the city's new drug treatment service, from July.
RISE Manchester has been commissioned by the Council's Drug& Alcohol Strategy Team (DAST), and the new service will be delivered in partnership by CRI, ADS (Addiction Dependency Solutions) and Lifeline.
RISE Manchester will provide comprehensive, recovery-focused treatment for Manchester residents with substance misuse problems. Services will be delivered from a range of treatment centres and community locations, including pharmacies, community centres and GP practices, to ensure ease of access for service users.
Stacey Smith, Deputy Director, CRI, said: "CRI is looking forward to working closely with our service delivery partners to provide a comprehensive, locality-based, recovery-oriented service model to meet the needs of local people with substance misuse problems."
CRI will manage the Clinical Service, providing integrated treatment for adults helping them to stabilise and reduce their drug use, facilitating recovery and promoting abstinence.
ADS will deliver the Intake Service, an easily accessible engagement and assessment service which enables adults to access appropriate recovery-focused treatment and support.
Lifeline will run the Recovery Service, delivering interventions to enable adults to become drug free and/or recover from their addiction to drugs. This includes promoting and supporting reintegration in housing and employment.
David Regan, Joint Director of Public Health, NHS Manchester and Manchester City Council, said: "This new contract is the culmination of a detailed process of consultation to redesign adult drug treatment services in Manchester. Our aim is to promote recovery through flexible, local services that address the impact of substance misuse on individuals, families and carers. Our new service model will provide the best possible opportunity for people to overcome their drug problems and regain their independence."
For general enquiries, please contact our regional offices:
All media and press enquiries should be directed to: